25
2019-10
[Suzhou, China, October 25, 2019] 真人直营投注网站 (the parent company of Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor")) and its subsidiaries (the "Group")announced completion of a financing of USD45 million in September 2019, which was a new round of financing after Series C investment of RMB288 million in February 2018. This round of investment was led by the Shanghai Free Trade Zone Fund, followed by Huajin Capital, CCB Technological Innovation Fund, Yicheng Hongtai, Yirongchuang and Guangzhou Chengfa. The original investor, Highlight Medical, also participated in this round of investment.
29
2019-08
How Many Blockbuster Novel Drugs Can Be Produced for Chinese Hair Loss Population of 250 Million?
Recently, a group of data indicating more than 250 million people with hair loss in China has circulated online and caused heated discussion. In fact, hair loss is a common disease worldwide. Under normal circumstances, a healthy person will have nearly a hundred hairs shed naturally every day, and an equal amount of hair will be reborn from the scalp hair follicles. If hair loses faster than growth of newborn hair, there will be hair loss problem, which will affect the aesthetics and mental health.
20
2019-08
mTOR Inhibitor Developed by Suzhou Kintor Obtained Approval for Clinical Trials in China
[Suzhou, August 20, 2019] National Medical Products Administration officially granted a clinical trial approval to Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") on commencement of clinical trials of the drug (GT0486) as an mTOR inhibitor. The drug (GT0486) is a novel mTORC1 / mTORC2 inhibitor (the second generation of mTOR inhibitor) which is indicated for advanced solid tumors. Currently, there is no second generation of mTOR inhibitors on the market in China, and there are huge unmet clinical needs in the research area.
19
2019-08
[Suzhou, August 19, 2019]Suzhou Kintor Pharmaceuticals, Inc. (“Suzhou Kintor") and CMAB Biopharma (Suzhou) Inc. ("CMAB") announced together a comprehensive strategic cooperation agreement on the development and production of ALK-1 monoclonal antibody in Suzhou Biopharma Industrial Park (BioBAY).
21
2019-06
Suzhou Kintor Won "Extraordinary Biopharmaceutical Enterprise Award" of China Financing in 2019
[June 21, 2019, Hong Kong, China] The awarding ceremony of the "2019 China Financing Awards" sponsored by "China Financing", a high-end financial magazine on Hong Kong capital market, was successfully held in Hong Kong. Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor"), together with nine pharmaceutical enterprises such as WuXi Biologics, Henlius, CanSinoBio, Innovent Biologics and Hua Medicine, won "Extraordinary Biopharmaceutical Enterprise Award" of China Financing in 2019. Dr. Youzhi Tong, Chairman and Chief Executive Officer of Suzhou Kintor , was invited to attend the ceremony and accept the award on behalf of the company.
29
2018-10
Blockbuster news! 2018 Dongsha Lake [Venture Capital] Annual List Came out!
The 2018 Dongsha Lake [Venture Capital] Carnival sponsored by Oriza Holdings was held in Suzhou Industrial Park on October 29. Top fund investors,fund managers,and outstanding entrepreneurs in domestic private equity investment industry gathered in Dongsha Lake Fund Town to discuss the future development of Chinese venture capital industry and share their insights on industry trends and investment logic.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn